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Despite current therapy with agents that block the
renin–angiotensin system, renal dysfunction continues to
progress in a significant proportion of patients with kidney
disease. Several pre-clinical studies have reported beneficial
effects of tranilast, an inhibitor of transforming growth factor
(TGF)-b’s actions in a range of diseases that are characterized
by fibrosis. However, whether such therapy provides
additional benefits in renal disease, when added to
angiotensin-converting enzyme (ACE) inhibition, has not
been explored. We randomized subtotally (5/6)
nephrectomized rats to receive vehicle, the ACE inhibitor,
perindopril (6 mg/l), tranilast (400 mg/kg/day), or their
combination for 12 weeks. When compared with
sham-nephrectomized animals, subtotally nephrectomized
animals had reduced creatinine clearance, proteinuria,
glomerulosclerosis, interstitial fibrosis, tubular atrophy, and
evidence of TGF-b activity, as indicated by the abundant
nuclear staining of phosphorylated Smad2. These
manifestations of injury and TGF-b activation were all
attenuated by treatment with either tranilast or perindopril,
with the latter also attenuating the animals’ hypertension.
When compared with single-agent treatment, the
combination of tranilast and perindopril provided additional,
incremental improvements in creatinine clearance,
proteinuria, and glomerulosclerosis, and a reduction in
nuclear phsopho-Smad2 beyond single-agent treatment.
These findings indicate that the combination of tranilast and
perindopril was superior to single-agent treatment on kidney
structure and function in the remnant kidney model, and
suggests the potential for such dual therapy in kidney
disease that continues to progress despite blockade of the
renin–angiotensin system.
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Chronic kidney disease is a common and increasing public
health problem in the US, Europe, and in most countries
where reliable epidemiological data are available. For
instance, in the US, approximately eight million people have
impaired renal function (calculated glomerular filtration
rate o60 ml/min/1.73 m2, with a further 300 000 individuals
in end-stage renal failure.1
Almost regardless of the insult, an initial critical nephron
loss is frequently followed by progressive proteinuria and
declining glomerular filtration rate, with an inexorable
progression to end-stage renal disease. Current renoprotec-
tive therapy, aimed at slowing this progression, centers on
blood pressure control and blockade of the renin–angiotensin
system, for which data from controlled clinical trials provide
a strong evidence base for treatment.2 However, despite these
important therapies, a considerable proportion of patients
with chronic kidney disease continue to progress and new
therapies are needed.
The pathological accumulation of extracellular matrix3
and tubular atrophy4 are classical histopathological features
of progressive kidney disease that each correlate with
declining renal function. Consistent with these findings,
experimental data accumulated over more than a decade have
repeatedly implicated the profibrotic and proapoptotic
growth factor, transforming growth factor-b (TGF-b), in
the pathogenesis of kidney injury,5 making it a key target for
renoprotective therapies.
To date, a number of strategies to reduce the expression or
antagonize the effects of TGF-b have been evolved, including
neutralizing TGF-b antibodies,6,7 the glycosaminoglycan,
decorin,8 and small-molecule inhibitors of TGF-b action.9
Among the latter is tranilast (n-[3,4-dimethoxycinnamoyl]
anthranilic acid), an antifibrotic agent used in Japan for the
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treatment of hypertrophic scars,10 which has been shown to
inhibit TGF-b-induced extracellular matrix production
synthesis in cultured kidney cells11 and to reduce renal
injury in a number of disease models.12–14
Given the effectiveness, albeit incomplete, of angiotensin-
converting enzyme (ACE) inhibitors and angiotensin recep-
tor blockers (ARBs), any new therapy in clinical practice
would need to be examined as an ‘add-on’ to these agents.
We, therefore, sought to examine the renoprotective effects
of combining tranilast with ACE inhibition, using the 5/6
nephrectomy model, a well-characterized model of non-
inflammatory proteinuric renal disease in which critical
nephron loss leads to progressive renal dysfunction.15 In this
model, TGF-b expression is increased but unaffected by
tranilast.12 Accordingly, in the present study, we also sought
to determine the effects of tranilast on TGF-b-dependent
collagen production.
RESULTS
Animal characteristics
All rats that underwent subtotal nephrectomy were hyper-
tensive and developed substantial proteinuria and reduced
creatinine clearance. Treatment of subtotal (5/6) nephrec-
tomy (STNx) rats with perindopril attenuated all of these
changes (Table 1). Tranilast also reduced proteinuria and
improved creatinine clearance, albeit to a lesser extent than
perindopril, but without affecting blood pressure. Without
additional blood pressure lowering, the addition of tranilast
to perindopril led to a further reduction in proteinuria and
incremental improvement in creatinine clearance when
compared with either drug as monotherapy (Table 1).
Histopathology
Subtotal nephrectomy led to significant glomerulosclerosis
and tubulointerstitial fibrosis (Figures 1–3), with the
proportional area of kidney cortex occupied by collagenous
matrix increased more than 10-fold (Po0.01; Figure 1)
compared with shams. Considerable inter-nephron hetero-
geneity in the extent of fibrosis and atrophy was also noted.
When used as monotherapy, perindopril, and tranilast each
reduced the extent of glomerulosclerosis in STNx rats,
although the magnitude of this reduction was greater with
perindopril than tranilast. The combination of the two agents
resulted in a still greater reduction in glomerulosclerosis
when compared with either single-agent treatment.
Tubular atrophy, absent in sham kidneys, was also a
prominent feature of STNx kidneys (Figures 3, 4) that was
reduced by perindopril and to a lesser extent by tranilast also.
However, when used together, the perindopril and tranilast
combination led to a greater diminution in the extent
of tubular atrophy when compared with either agent as
monotherapy.
All treatments substantially reduced the degree of inter-
stitial fibrosis to a similar extent (Figures 1–4).
Phosphorylated Smad2
In contrast to its minimal immunostaining in sham animals,
abundant phosphorylated Smad2 was noted in STNx kidneys
(Figures 5, 6), where it was confined to the nuclei and noted
Table 1 | Animal characteristics
Sham STNx STNx+tranilast STNx+perindopril STNx+tranilast+perindopril
N 10 10 15 15 17
Body weight (g) 560718 51679 475716 512713 514712
SBP (mm Hg) 135710 193711w 19979w 13178w,z 12479w,z
Proteinuria (mg/day) 1.370.12 6.2470.94w 4.570.71z 2.570.43z 0.7170.24z,y
Creatinine clearance (ml/min) 2.770.14 0.6070.11w 0.8670.10w 1.2370.16z 1.3670.11z,y
SBP, systolic blood pressure; STNx, subtotal (5/6) nephrectomy. Data are expressed as mean7s.e.m. *Po0.05, wPo0.01 versus sham, zPo0.05, zPo0.01 versus STNx, yPo0.05
versus STNx+perindopril.
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Figure 1 | Glomerulosclerotic Index (upper panel) and tubuloin-
terstitial fibrosis (lower panel) in sham and STNx rats treated
with tranilast, perindopril, or a combination of tranilast and
perindopril. Data are presented as mean7s.e.m. *Po0.01 compared
with shams, wPo0.01 versus untreated STNx rat kidneys. zPo0.05
versus STNxþ tranilast. #Po0.05 versus monotherapy.
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to be particularly prominent in areas of fibrosis and atrophy
(Figure 6). In contrast, phosphorylated Smad2 immuno-
staining was substantially lower in STNx rats treated with
perindopril and with tranilast. However, animals treated with
the combination of perindopril and tranilast showed less
phosphorylated Smad2 immunostaining than did rats treated
with either agent as monotherapy. Glomerular and tubulo-
interstitial regions showed similar patterns of phosphorylated
Smad2 immunostaining.
In vitro studies. In cultured rat mesangial cells, TGF-b led
to a significant increase in extracellular matrix production, as
measured by 3H-proline incorporation. This was attenuated
by tranilast at 100 mM, although 3H-proline incorporation
remained higher than in controls. However, at 300 mM
tranilast, 3H-proline incorporation was similar to that in
control cells (Figure 7).
DISCUSSION
Pivotal experimental studies16,17 and small clinical trials,18,19
performed more than two decades ago, first demonstrated
the beneficial effects of blood pressure lowering and later
ACE inhibitor therapy on the progression of kidney disease,
laying the foundations for major clinical trials in both
diabetic20–22 and non-diabetic kidney disease.23,24 However,
despite the widespread use of ACE inhibitors and ARBs in
kidney disease, renal dysfunction continues to progress in the
majority of patients, eventually leading to end-stage renal
disease, in those who do not succumb to its co-morbidities.
The present study demonstrates that therapy designed to
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Figure 2 | Representative photomicrograph of periodic acid
Schiff-stained sections from Sham, STNX rats treated with
tranilast, perindopril, or a combination of tranilast and peri-
ndopril. In (a) sham rats there is no glomerulosclerosis, while
(b) STNx is associated with a dramatic increase in glomerulosclerosis.
Treatment of STNx rats with (c) tranilast and (d) perindopril was
associated with a reduction in extent of glomerulosclerosis.
(e) Combination therapy with tranilast and perindopril was
associated with less glomerulosclerosis than monotherapy. Original
magnification  360.
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Figure 3 | Representative trichrome-stained sections showing
tubulointerstitial fibrosis and atrophy in Sham, STNx rats treated
with tranilast, perindopril, or a combination of tranilast and
perindopril. In (a) sham, there is no cortical tubular fibrosis or
atrophy, while (b) STNx is associated with an increase in interstitial
fibrosis (blue) and atrophic tubules (arrows). Treatment of STNx rats
with (c) tranilast, (d) perindopril, and (e) combination therapy was
associated with a reduction in both tubular fibrosis and atrophy.
Original magnification  380.
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Figure 4 | Quantitation of atrophic tubules in rat kidneys from
sham, STNx rats treated with tranilast, perindopril, or a
combination of tranilast and perindopril. Data are presented as
mean7s.e.m. *Po0.01 compared with shams, wPo0.01 versus
untreated STNx rat kidneys. zPo0.05 versus STNxþ tranilast. #Po0.05
versus monotherapy.
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antagonize the effects of TGF-b, another pathogenetic factor
in renal disease, resulted in an incremental renoprotective
effect on the structural and functional manifestations of renal
injury in the subtotally nephrectomized rat, when added to
background ACE inhibitor therapy.
TGF-b is a multi-functional cytokine that has long
been associated with the pathogenesis of progressive kidney
disease, implicated in particular, with the development of
fibrosis and atrophy.25,26 It is synthesized as a 391 amino-acid
precursor molecule with little biological activity, requiring
cleavage of its N-terminal latency-associated peptide to give
rise to its active form. In addition, the biological effects of
TGF-b may also be modified by the presence of the
proteoglycan decorin27 and the scavenging protein alpha
2-macroglobulin.28 Given these factors that may modulate
TGF-b activity, we therefore assessed its biological effects
by examining one of its specific intracellular actions, the
phosphorylation and nuclear translocation of the TGF-b
receptor-activated protein, Smad2.29 Although only minimal
phospho-Smad2 immunostaining was detected in the kidney
of sham rats, those from subtotally nephrectomized animals
showed prominent nuclear staining of phosphorylated
Smad2. In contrast to untreated animals, those receiving
either tranilast or perindopril as single agents showed
substantial reductions in nuclear phospho-Smad2. Moreover,
the combination of the two agents resulted in further
incremental reductions in nuclear phospho-Smad2 that were
greater than seen when either agent was used on its own.
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Figure 5 | Quantitation of tubulointerstitial (upper panel) and
glomerular phospho-Smad 2 (lower panel) immunostaining in rat
kidneys from sham, STNx rats treated with tranilast, perindopril,
or a combination of tranilast and perindopril. *Po0.01 compared
with shams, wPo0.01 versus untreated STNx rat kidneys. zPo0.05
versus STNxþ Tran. #Po0.05 versus monotherapy.
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Figure 6 | Representative photomicrographs of (a–e) glomeruli and (f–j) tubulointerstitium immunostained for phospho-Smad 2 in
Sham, STNx rats treated with tranilast, perindopril, or a combination of tranilast and perindopril. In (a, f) sham there is little evidence of
phospho-Smad 2, while (b, g) STNx is associated with an increase immunostaining for phospho-Smad 2. (c, h) Treatment of STNx rats with
tranilast, (d, i) perindopril, and (e, j) combination therapy was associated with an incremental reduction in phospho-Smad 2 immunostaining in
the tubular epithelium. Original magnification  380.
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Figure 7 | In vitro effects of tranilast on TGF-b induced 3H-proline
incorporation in cultured rat mesangial cells. Values are expressed
as mean7s.e.m. *Po0.01 versus cells grown in control medium,
wPo0.01 versus TGF-b-treated cells.
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Blood pressure reduction and blockade of the renin–-
angiotensin system are key elements in attenuating the
progression of chronic renal disease. We therefore used a dose
of perindopril that in previous dose-finding studies by our
group had been shown to effectively reduce blood pressure
and provide renal protection,30 with higher doses of the
compound failing to provide further benefit.31 As previously
described in the 5/6 nephrectomy model,12,16 treatment with
either tranilast or ACE inhibitor, in the present report, led
to improved glomerular filtration rate and diminution in
proteinuria. However, in contrast to perindopril, tranilast
exerted its renoprotective effects without affecting hyperten-
sion. Moreover, despite its lack of effect on systemic pressure,
‘add-on’ therapy with tranilast led to further incremental
benefits on glomerular filtration rate and proteinuria beyond
that with perindopril alone.
Histopathologically, kidney disease is characterized by
glomerulosclerosis, tubulointerstitial fibrosis, and atrophy.
When used as monotherapy, tranilast and perindopril each
reduced the extent of glomerulosclerosis and tubulointerstitial
fibrosis in subtotally nephrectomized rats. Moreover, when
both drugs were used in combination, a further reduction in
glomerulosclerosis, beyond that seen with single-agent treat-
ment, was also noted. In addition to fibrosis, tubular atrophy
has also been long recognized as an indicator of renal disease
severity and progression,4,32 where its development is thought
to reflect apoptosis, rather than necrosis of epithelial cells.33,34
Consistent with previous reports, we also found that both
ACE inhibition and tranilast treatment reduced tubular
atrophy.12,35 However, the combination of these two agents,
as used in the present study, showed a further beneficial effect
on the extent of tubular atrophy, beyond that found with
either single-agent treatment.
Overexpression of TGF-b is a characteristic feature of
many human kidney diseases and of the 5/6 nephrectomy
model in rats.35 Although ACE inhibitors and ARBs attenuate
this overexpression, tranilast does not.12 However, as shown
in the present study, tranilast effectively reduces TGF-b-
induced collagen production. These separate, but related
mechanisms of RAS blockade and tranilast in inhibiting TGF-
b are consistent with their additive effects of these agents
when used together in the setting of progressive renal disease.
In clinical studies, additional renal protection can be
achieved with increasing the dose of ARB36 or by combining
ARBs and ACE inhibitor together.37 In our own studies, we
have previously explored the dose–response relationship
between renal protection and perindopril dose, demonstrat-
ing a maximal perindopril effect at 2 mg/kg/day and also
showing that higher doses of perindopril such as the 6 mg/kg/
day, used in the present study, have similar efficacy to
combining perindopril with the ARB, valsartan.30,31 Accord-
ingly, in the current study, we used the 6 mg/kg/day dose
to determine whether an alternative non-RAS-dependent
treatment may provide additional efficacy.
Agents used in experimental studies to antagonize the
effects of TGF-b in kidney disease have included neutralizing
antibodies7 and the proteoglycan, decorin.27 In the present
study, we explored an alternative approach, using an orally
active compound that is currently in clinical use, and that
has previously been shown to block TGF-b-induced fibrosis
in vitro11,38,39 and in a number of in vivo settings.11,12,14,40
The findings of the present study thus complement those in
other disease models that have examined the effects of adding
TGF-b inhibitory strategies to background therapy with ACE
inhibitor or ARB. For instance, in studies of experimental
diabetic nephropathy, Benigni et al6 found that the addition
of the TGF-b neutralizing monoclonal antibody, 1D11, to
lisinopril led to an incremental attenuation of renal injury.
Similarly, in studies of experimental mesangial proliferative
glomerulonephritis, using the same antibody, Yu et al41 also
reported additional benefits by combining this agent with
enalapril. In the present study, we examined animals that
had undergone STNx. This well-characterized model of
non-inflammatory proteinuric renal disease features many of
the structural and functional attributes of chronic progressive
kidney disease in humans, leading to its frequent use in
exploring the pathogenetic pathways that contribute to the
relentless progressive nature of kidney disease.42
In summary, treatment with tranilast in addition to ACE
inhibitor therapy resulted in an incremental attenuation in
the structural and functional manifestations of injury in
association with evidence of reduced activation of the TGF-
b-signalling pathway. In the context of a recent pilot study in
humans combining tranilast with RAS blockade in diabetic
nephropathy,43 the findings of the present study suggest that
tranilast may also provide a novel strategy for the treatment of
non-diabetic kidney disease characterized by fibrotic scarring.
MATERIALS AND METHODS
Animals
A total of 80 male Sprague–Dawley rats weighing 200–250 g were
randomized to eight groups of 10 animals each. Anesthesia was
achieved by the intraperitoneal administration of pentobarbital
(6 mg/100 g body weight, Boehringer Ingelheim, Artarmon, NSW,
Australia). A total of 60 rats underwent STNx performed by right
subcapsular nephrectomy and infarction of approximately two-thirds
of the left kidney by selective ligation of two of 3–4 extrarenal
branches of the left renal artery. Animals were then randomly
assigned to the following groups: STNx and vehicle or STNx with
either tranilast (400 mg/kg/day by twice daily gavage, Pharm
Chemical, Shanghai Lansheng Corporation, China), perindopril
(6 mg/kg/day, drinking water) or a combination of tranilast and
perindopril. The control group underwent sham surgery consisting of
laparotomy and manipulation of both kidneys before wound closure.
Rats were housed in a temperature (221C)-controlled room with ad
libitum access to commercial standard rat chow (Norco Co-Operative
Ltd, Lismore, NSW, Australia) and water during the entire study. Rats
from each group were killed at 12 weeks postsurgery. On killing, the
remnant (left) kidney was excised, decapsulated, then sliced sagitally
with one-half immersion fixed in 10% neutral-buffered formalin and
embedded in paraffin for histology, and the other half frozen in liquid
nitrogen. All experiments adhered to the guidelines of the Animal
Welfare and Ethics Committee of the St Vincent’s Hospital and the
National Health and Medical Research Foundation of Australia.
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Renal function
Body weight was measured weekly. Plasma creatinine was measured
by autoanalyzer (Beckman Instrumentals, Palo Alto, CA, USA) at the
beginning and end of the study. Systolic blood pressure was measured
in conscious rats using an occlusive tail-cuff plethysmograph
attached to a pneumatic pulse transducer (Narco Bio-system Inc.,
Houston, TX, USA). Before killing, rats were housed in metabolic
cages for 24 h for subsequent measurement of urinary creatinine and
albumin excretion using a rat-specific radioimmune assay.44
Tissue preparation
Rats were anesthetized (Nembutal 60 mg/kg body weight intraperi-
toneally, Boehringer-Ingelheim, Australia) and the abdominal aorta
cannulated with an 18-G needle. Perfusion–exsanguination com-
menced at SBP (180–220 mm Hg) via the abdominal aorta with
0.1 M phosphate-buffered saline, pH 7.4 (20–50 ml) to remove
circulating blood, and the inferior vena cava adjacent to the renal
vein was simultaneously severed, allowing free flow of the perfusate.
After clearance of circulating blood, 10% buffered formalin was
perfused for a further 5 min (100–200 ml) to fix the tissues.
Histopathology
Changes in kidney structure were assessed in a masked protocol in at
least 25 randomly selected tissue sections from each group studied.
Sections were stained with Mayer’s hematoxylin and eosin, periodic
acid Schiff ’s stain, or Masson’s modified trichrome to demonstrate
collagen matrix.
Glomerulosclerosis
The extent of glomerulosclerosis was determined in 3mm kidney
sections stained with periodic acid Schiff ’s stain, as described
previously.35 In brief, 50–80 glomeruli from each rat were examined
in a masked protocol. The degree of sclerosis in each glomerulus was
graded on a scale of 0–4 as described previously with Grade 0, normal;
Grade 1, sclerotic area upto 25% (minimal); Grade 2, sclerotic area
25–50% (moderate); Grade 3, sclerotic area 50–75% (moderate to
severe), and Grade 4, sclerotic area 75–100% (severe). A glomerulo-
sclerotic index (GSI) was then calculated using the formula:
4
GSI ¼P FiðiÞ
i ¼ 0
where Fi is the fraction of glomeruli in the rat with a given score (i).
Tubular atrophy
Tubular atrophy was assessed in kidney sections stained with
Masson’s trichrome. At  40 magnification (Olympus BX-50 light
microscope, Olympus, Tokyo, Japan), six random and non-
overlapping fields from each slide (two slides analyzed for N¼ 6
rats/group) were selected. Atrophic tubules were identified as
described previously,26 with results expressed as the number of
atrophied tubules per field of kidney cortex.
TGF-b receptor activation
Activation of the TGF-b receptor was assessed by quantifying the
nuclear expression of phosphorylated Smad2 using a rabbit anti-
phospho-Smad2 antibody (Cell Signalling Technology, Boston, MA,
USA) that detects endogenous Smad2 only when dually phosphory-
lated at Ser463 and Ser465. Sections were immunostained, as
described previously,45 according to the manufacturer’s instructions.
Sections incubated with 1:10 NGS, instead of the primary
antiserum, served as the negative control.
Quantitation of matrix deposition and phospho-Smad2
expression
The extent of phospho-Smad2 immunostaining was also quantified
using computer-assisted image analysis, as reported previously.12 For
glomerular phospho-Smad2, 10 glomeruli were examined from each
rat and the number of glomerular nuclei that showed phospho-
Smad2 immunolabelling were counted and expressed as positive
nuclei/per glomerulus. For the tubulointerstitium, five random non-
overlapping fields from six rats per group were captured and
digitized using a BX50 microscope attached to a Fujix HC5000
digital camera. Digital images were then loaded onto a Pentium III
IBM computer. The accumulation of matrix within the tubulointer-
stitium was similarly assessed on Masson’s trichrome-stained sections
using computer-assisted image analysis, as reported previously.46,47
An area of blue on a trichrome-stained sections (for matrix) or
brown on immunostained sections (for phospho-Smad2) were
selected for their color ranges and the proportional area of tissue
with their respective ranges of color was then quantified. Calculation
of the proportional area stained blue (matrix) or brown (phospho-
Smad2) was then determined using image analysis (AIS, Analytical
imaging Station Version 6.0, Ontario, Canada).
Cell culture studies
To determine the effects of tranilast on glomerular collagen
production in vitro, we studied a well-characterized cloned rat
mesangial cell line48 (gift of David Nikolic-Patterson), which was
cultured in Dulbecco’s modified Eagle’s medium (GibcoTM; Invitro-
gen, Grand Island, NY, USA) with fetal bovine serum, 100 U/ml
penicillin, and 100 mg/ml streptomycin in humidified 5% CO2
atmosphere at 371C. Cells were plated into 24-well dishes at low
density and allowed to attach overnight. The subconfluent cells were
then serum starved overnight in 0.1% fetal bovine serum before
treatment with or without tranilast. Tranilast, 100 and 300 mM, was
then added to the wells, followed 4 h later by 3H-proline (1mCi/well)
and TGF-b 5 ng/ml (R&D systems, Minneapolis, MN, USA). Cells
were harvested 48 h poststimulation, washed twice with ice-cold
phosphate-buffered saline, and twice with 10% trichloroacetic acid,
500 ml 1 M NaOH, and then neutralized with 500 ml 1 M HCl.
Incorporation of exogenous 3H-proline (L-[2,3,4,5-3H]-proline;
Amersham Biosciences, Piscataway, NJ, USA) was then measured
using a liquid scintillation counter (Wallac 1410; Amersham
Biosciences). Cell viability was assessed by trypan blue exclusion.
Statistics
Data are expressed as means7s.e.m. unless otherwise stated.
Statistical significance was determined by a two-way analysis of
variance with a Fishers post-hoc comparison. Owing to its skew
distribution, data on albuminuria were log transformed prior to
analysis and expressed as geometric mean x/tolerance factor. All
analyses were performed using Statview II þ Graphics package
(Abacus Concepts, Berkeley, CA, USA) on an Apple Macintosh G4
computer (Apple Computer Inc., Cupertino, CA, USA). A P-value
o0.05 was regarded as statistically significant.
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